Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Spyre Therapeutics, Inc. (SYRE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Spyre is a clinical-stage biotechnology company listed on the Nasdaq Global Select Market, and its filings document material events, financing activities, and key clinical development updates related to its long-acting antibody programs for inflammatory bowel disease and rheumatic diseases.
Recent Form 8-K reports describe, for example, interim Phase 1 results for SPY003, an investigational extended half-life antibody targeting the p19 subunit of IL-23, including safety and pharmacokinetic findings that the company states support potential quarterly or twice-yearly maintenance dosing. Other 8-K filings detail the initiation and structure of the SKYLINE Phase 2 platform trial in ulcerative colitis and the SKYWAY Phase 2 basket trial in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, as well as financial results and preliminary cash balances for specific quarters.
Spyre’s filings also include disclosures about public equity offerings under its shelf registration statement on Form S-3. An 8-K dated October 15, 2025, for example, outlines the terms of an underwritten public offering of common stock, gross proceeds, and the company’s stated intention to use net proceeds to advance programs in IBD and rheumatic diseases, support preclinical and clinical work, manufacturing, and Phase 3 readiness activities, and provide working capital.
On Stock Titan, users can review these filings in sequence and use AI-powered tools to summarize lengthy documents, highlight key sections, and quickly identify items related to clinical data, financing, and other material events disclosed by Spyre Therapeutics.
Spyre Therapeutics CFO Scott L. Burrows reported a sell-to-cover transaction tied to the settlement of restricted stock units. The filing shows 18,428 shares of common stock were sold at a weighted average price reported near $16.26, generated to satisfy tax withholding obligations arising from the settlement of 33,738 RSUs. Following the sale, the reporting person beneficially owns 97,994 shares outright.
The report also discloses an additional 67,476 RSUs that remain outstanding; those RSUs vest in two equal installments on September 1, 2026 and September 1, 2027, subject to continued employment. The transaction is described as non-discretionary and solely for tax withholding.